| Seizures, Focal
Briviact vs Qudexy XR
Side-by-side clinical, coverage, and cost comparison for seizures, focal.Deep comparison between: Briviact vs Qudexy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQudexy has a higher rate of injection site reactions vs Briviact based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qudexy but not Briviact, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Briviact
Qudexy
At A Glance
Oral; IV infusion
Twice daily
SV2A ligand
Oral
Once daily
Broad-spectrum anticonvulsant
Indications
- Seizures, Focal
- Seizures, Focal
- Generalized seizures
- Lennox-Gastaut syndrome
- Migraine Disorders
Dosing
Seizures, Focal Adults (>=16 years): 50 mg twice daily (range 25-100 mg twice daily); pediatric patients >=50 kg: 25-50 mg twice daily (range 25-100 mg twice daily); pediatric patients <50 kg: weight-based dosing twice daily; IV injection at the same dose when oral administration is temporarily not feasible; dose adjustment required for all stages of hepatic impairment.
Seizures, Focal, Generalized seizures, Lennox-Gastaut syndrome Monotherapy (adults and peds >=10 years): 400 mg orally once daily, titrated over 6 weeks from 50 mg/day; peds 2-9 years: weight-based 150-400 mg/day once daily. Adjunctive (adults): 200 to 400 mg once daily; adjunctive (peds 2-16 years): approximately 5 to 9 mg/kg once daily, not to exceed 400 mg/day.
Migraine Disorders 100 mg orally once daily for patients 12 years of age and older, titrated over 4 weeks from 25 mg/day.
Contraindications
- Hypersensitivity to brivaracetam or any inactive ingredient in BRIVIACT (bronchospasm and angioedema have occurred)
- History of hypersensitivity reaction to topiramate, QUDEXY XR, or any inactive ingredient
Adverse Reactions
Most common (>=5%) Somnolence and sedation, dizziness, fatigue, nausea and vomiting symptoms
Serious Suicidal behavior and ideation, neurological adverse reactions, psychiatric adverse reactions, hypersensitivity (bronchospasm and angioedema), serious dermatologic reactions, hematologic abnormalities (decreased white blood cell and neutrophil counts)
Postmarketing Serious dermatologic reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis)
Most common (>=10%) Paresthesia, somnolence, dizziness, weight loss, anorexia, speech disorders/related speech problems, psychomotor slowing, nervousness, vision abnormal
Serious Acute myopia and secondary angle closure glaucoma, visual field defects, oligohydrosis and hyperthermia, metabolic acidosis, suicidal behavior and ideation, cognitive/neuropsychiatric adverse reactions, decrease in bone mineral density, negative effects on growth, DRESS/multiorgan hypersensitivity, serious skin reactions, anaphylaxis and angioedema, hyperammonemia and encephalopathy, kidney stones, hypothermia with concomitant valproic acid
Postmarketing Hepatic failure, hepatitis, pancreatitis, bullous skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), pemphigus, maculopathy, nephrocalcinosis
Pharmacology
Brivaracetam is an anticonvulsant with high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain; the precise mechanism by which it exerts anticonvulsant activity is not fully established.
Topiramate blocks voltage-dependent sodium channels, augments GABA-A receptor activity, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits carbonic anhydrase isozymes II and IV; the precise mechanisms underlying its anticonvulsant and preventive migraine effects are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Briviact
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (3/12) · Qty limit (0/12)
Qudexy
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Briviact
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (3/8) · Qty limit (0/8)
Qudexy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Briviact
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Qudexy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/momo
Briviact Patient Savings CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Qudexy.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BriviactView full Briviact profile
QudexyView full Qudexy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.